ABSTRACT: HIV-positive individuals, who are at high risk of developing cancers such as Kaposi's sarcoma, tend to be more sensitive to ionizing radiation and are at a higher risk of developnew and noninvasive methods are needed to sensitize cancer cells and reduce therapeutic doses.
I. INTRODUCTION
The treatment of HIV/AIDS-related Kaposi's sarcoma (KS) (also known as epidemic -tent, symptoms, and overall patient condition. Epidemic KS may be treated with several the HIV infection, using highly active antiretroviral therapy (HAART), which is known to reduce the severity of KS in AIDS patients. 1 HAART alone, however, may not reverse progression of KS, and other treatments are necessary, such as surgery, chemotherapy, radiation therapy, and biological therapy. The best response is found with radiation ther--tion therapy because a compromised immune system may not have the capacity to repair radiation-induced damage. 2 This cohort of cancer patients tends to show higher normal tissue toxicity during conventional radiotherapy than their HIV-negative counterparts. [3] [4] [5] [6] [7] Radiation therapy can also further weaken the immune system, and so patients with HIV/AIDS may not be able to complete the full course of treatment without risking modalities are needed for the treatment of epidemic KS.
of cutaneous KS, with less normal tissue toxicity than the conventional regimens.
2,4
However, such a high dose may cause greater tissue toxicity, from which HIV/AIDS patients, and it was noted that acute toxicity increased with increasing radiation dose. 4 Because the number of HIV/AIDS patients presenting with KS is increasing and patients are expected to exhibit lower levels of treatment tolerance compared to their non-AIDS infected counterparts, combining radiation therapy with other modalities might be ben- [8] [9] [10] In vitro studies have also shown -tosis. [11] [12] [13] [14] [15] future use in noninvasive and nontoxic therapeutic approaches for cancer treatment. 16 type. 17 This outcome suggests that informed combination of low to medium frequency -pecially those in HIV-positive patients. Most entities that interact synergistically with EMFs are mutagens; therefore synergism between EMFs and ionizing radiation should be considered more seriously.
II. MATERIALS AND METHODS

A. Cell Cultures
The V79 cell line (ATCC ® Number: CCL-93™), used to mimic normal tissue, was derived from Chinese hamster lung and was obtained from Flow Laboratories (Irvine, ® Number: HTB-65™) was routinely grown as monolayers in 75-cm an output impedance of 50 a double bubble argon plasma ray tube, which was assumed to function as an antenna T, 0.09 to 0.42 V/m, and 0.14 to 0.63 A/m 2 , respectively. 17 Cell cultures were exposed to EMF exposure (0 Hz), the control samples were treated as described with the plasma
D. Clonogenic Cell Survival
Cell survival was evaluated by the colony forming assay as described previously. 
E. Statistical Analysis
Diego, CA, USA) computer program. To compare two data sets, the unpaired two-sided t-test was used. A P between the data sets. Data were presented as the mean (± SEM) from at least three independent experiments. For each experiment, three replicates were assessed. Errors for calculated quantities were derived, using appropriate error propagation formulae.
III. RESULTS AND DISCUSSION
This study sought to compare the outcomes of a split dose of radiation and an acute dose ± 0.0253 and 0.2401 ± 0.0099, respectively ( Figs. 1 and 2 ). The disparity in intrinsic radiosensitivity gene is mutated in both cell lines.
18,19 Radiation-induced cell death is not necessarily dependent on p53 status. 20 is, therefore, likely due to activation of other genes upstream of p53 (e.g., ATM) that are responsible for p53-independent cell death in the former cell line, 21 making the cells explain the disparity in radiosensitivity. The role of DNA repair in cellular radiosensitivin the surviving fraction to 0.5620 ± a 1.59-fold increase to 0.3825 ± 0.0035 for the melanoma cells (see Fig. 2 and Table 1 ).
to suggest that conventional fractionated radiation therapy alone might not be very benHowever, to test whether fractionated radiotherapy is superior to combining a sinfractions, 6 h apart, were compared with those obtained when cells were treated with a P 0.0132). -sure. The corresponding relative responses (RR) ranged from 1.11 to 1.32, indicating a percentage increase in radioresistance of 11% to 32%, respectively (see Table 1 ). No 1.06 ± to 30% reduction in total radiation dose and a minimization of normal tissue toxicity.
FIG. 1:
Mean surviving fractions ( SEM) from three independent experiments for Chinese -tal dashed line represents the surviving fraction of untreated cultures. The solid arrow indicates the split dose surviving fraction against which combination treatments are compared. ***P 0.0009; **0.0009 P 0.001; *0.01 P 0.04.
FIG. 2:
Mean surviving fractions ( SEM) from three independent experiments for human melaline represents the surviving fraction of untreated cultures. The solid arrow indicates the split dose surviving fraction against which combination treatments are compared. ***P 0.0009.
ing are frequently encountered.
22-27 However, if the increased radioresistance of the healing may not be realized, because such proliferation is known to correlate with wound healing morbidity.
28 1000 Hz) 6 h later yielded either the same or an increase in radioresistance, in comparison with that found for the split dose irradiation (see Fig. 2 ). The corresponding relative responses emerged as 1.02 ± 0.01 and 1.47 ± 0.01 (see Table 1 ). Also, when -viving fraction was obtained (RR = 1.88 ± 0.04; a more than 80% increase in cell survival). These data indicate that pre-irradiation followed by 100 Hz exposure, or pre-exposure to 100 Hz followed by irradiation may lead to tumor resistance to radiotherapy. However, pre-exposure of the malignant cells to 1000 Hz resulted in a P = 0.0008). The corresponding relative response was 0.88 ± 0.01, representing a 12% decrease in cell survival. As in nontoxic (see Fig. 2 ). fractions of the split irradiation were given 6 h apart, and EMF exposure (100 or 1000 Hz) was radiosensitivity with respect to the split irradiation regimen, respectively. 
Cell line
IV. CONCLUSION
with epidemic KS, because this treatment radiosensitizes tumors and enhances the ratissue toxicity. EMFs, therefore, could be used with radiotherapy to reduce the total immunocompromised. There is a great need for the standardization of EMF therapy so that it may be used in cancer treatment. It is noninvasive and may potentially replace or enhance other therapeutic modalities, such as radiation therapy, surgery, and chemotherapy. As the number of HIV/AIDS cases continues to rise, epidemic KS cases are also on the increase. Radiation therapy plays a palliative role, and combining it with EMF therapy may even lead to better treatment outcomes. The data reported here demonstrate that the use of EMF in combination with radiation therapy may yield better results than conventional or hypofractionated radiation therapy.
